MILAN — Treatment of rheumatoid arthritis (RA) with tumor necrosis factor inhibitors (TNFi) does not appear to demonstrate a consistent and significant risk for demyelinating disease, according to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback